Interested in Eli Lilly and Company? Here are five stocks we like better.
Moderna's mRNA cancer vaccine, developed with Merck, succeeded in a late-stage melanoma trial, sending shares up 177% and boosting the broader biotech sector.
Eli Lilly, the world's largest pharmaceutical company, is nearing a 52-week high driven by its GLP-1 franchise and new oral-drug pipeline catalyst.
Natera has surged over 40% year to date on accelerating revenue growth and **** yst support, though its rich valuation reflects a momentum-driven growth profile.
The biotech sector just got the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence.
#lilly #company #cancer
Moderna's mRNA cancer vaccine, developed with Merck, succeeded in a late-stage melanoma trial, sending shares up 177% and boosting the broader biotech sector.
Eli Lilly, the world's largest pharmaceutical company, is nearing a 52-week high driven by its GLP-1 franchise and new oral-drug pipeline catalyst.
Natera has surged over 40% year to date on accelerating revenue growth and **** yst support, though its rich valuation reflects a momentum-driven growth profile.
The biotech sector just got the kind of catalyst that can define a cycle. On Wednesday, Moderna (NASDAQ: MRNA) stunned the market when its personalized mRNA cancer vaccine, developed with Merck (NYSE: MRK), became the first such therapy to succeed in a late-stage trial, reducing the risk of melanoma recurrence.
#lilly #company #cancer
2 months ago
